Commitment and Contingencies - Additional Information (Details) - USD ($) |
Mar. 31, 2019 |
Dec. 31, 2018 |
Jun. 30, 2018 |
Jun. 30, 2016 |
Nov. 18, 2015 |
|---|---|---|---|---|---|
| Other Commitments [Line Items] | |||||
| Purchase obligation | $ 1,571,000 | $ 1,604,000 | $ 2,805,000 | ||
| Pfizer License Agreement | Minimum | |||||
| Other Commitments [Line Items] | |||||
| Potential future regulatory milestone and sales milestone payments upon achievement of net sales | $ 250,000,000 | ||||
| Pfizer License Agreement | Maximum | |||||
| Other Commitments [Line Items] | |||||
| Potential future regulatory milestone and sales milestone payments upon achievement of net sales | $ 1,000,000,000 | ||||
| Supplemental Agreement | |||||
| Other Commitments [Line Items] | |||||
| Purchase obligation | $ 2,300,000 |
| X | ||||||||||
- Definition Potential future regulatory and sales milestone payments upon achievement of net sales. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|